Aerosol Inhalation Treatment for Dyspnea

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborator: National Institute of Nursing Research (NINR)
• Treatments: Furosemide

Criteria

Inclusion Criteria:

• Healthy

Exclusion Criteria:

• Unstable heart or circulation disease

• Stroke

• Seizure disorder

• Severe migraine headaches

• Liver or kidney disease

• Adrenal gland problem (Pheochromocytoma)

• Nerve problems that may affect your breathing sensation

• Brain cancer

• Drug or alcohol problem

• Systemic lupus erythematosis (SLE)

• High levels of depression, panic disorder, or other significant mental health problems

• Serious ongoing pain

• Pregnant

• Under 18 years old

• Not Fluent in English